AGF Management Ltd. Makes New $377,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

AGF Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,669 shares of the company’s stock, valued at approximately $377,000.

Several other large investors have also recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after acquiring an additional 1,739 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company’s stock valued at $92,000 after acquiring an additional 715 shares during the period. KLP Kapitalforvaltning AS increased its stake in shares of Teva Pharmaceutical Industries by 2.0% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 366,359 shares of the company’s stock valued at $6,140,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Vontobel Holding Ltd. raised its holdings in Teva Pharmaceutical Industries by 5.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 719,676 shares of the company’s stock worth $12,062,000 after purchasing an additional 37,455 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Down 0.4%

Shares of NYSE TEVA opened at $34.81 on Friday. The stock has a market cap of $39.92 billion, a PE ratio of 29.00, a P/E/G ratio of 1.99 and a beta of 0.70. The company has a current ratio of 1.04, a quick ratio of 0.82 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $37.35. The company has a 50-day moving average of $31.27 and a 200 day moving average of $23.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm posted $0.71 EPS. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on TEVA. The Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Scotiabank lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, Jefferies Financial Group boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $36.00.

Insider Activity

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 422,060 shares of company stock worth $12,254,965. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.